Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of RP7214 in Healthy Volunteers
NCT04680429Phase 1Completed
- Sponsor
- Rhizen Pharmaceuticals AG
- Start
- Dec 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RP7214 in coronavirus disease 2019 (COVID-19) and acute myeloid leukemia (AML) (5 arms), sponsored by Rhizen Pharmaceuticals AG. Primary endpoint: Assessments of Adverse Events (AEs). Started Dec 2020; status: completed.
02
Drugs
RP7214
03
Conditions
coronavirus disease 2019 (COVID-19)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04680429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04680429.